Limits...
ALDH1 expression correlates with favorable prognosis in ovarian cancers.

Chang B, Liu G, Xue F, Rosen DG, Xiao L, Wang X, Liu J - Mod. Pathol. (2009)

Bottom Line: Expression of ALDH1 was found in 48.9% of the samples.Fisher's exact test suggested that high expression of ALDH1 was significantly associated with endometrioid adenocarcinoma (P<0.0001), early-stage disease (P=0.006), complete response to chemotherapy (P<0.05), and a low serum level of CA125 (P=0.02).High percentage of cells expressing ALDH1 was associated with a longer overall survival time (P=0.01) and disease-free survival time (P=0.006) by log-rank test.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

ABSTRACT
Aldehyde dehydrogenase 1 (ALDH1), a detoxifying enzyme responsible for the oxidation of intracellular aldehydes, was shown to have a function in the early differentiation of stem cells, through its function in oxidizing retinol to retinoic acid. It has been shown that ALDH1 is a predictor of poor clinical outcome in breast cancer. The authors hypothesized that the level of ALDH1 expression may be correlated with the clinical outcome of patients with ovarian cancer. Immunohistochemical staining of ALDH1 expression was analyzed in 442 primary ovarian carcinomas using tissue microarray. The associations between the expression of the ALDH1 and clinical factors (diagnosis, tumor grade, stage, and clinical response to chemotherapy), as well as overall and disease-free survival, were analyzed. Expression of ALDH1 was found in 48.9% of the samples. Fisher's exact test suggested that high expression of ALDH1 was significantly associated with endometrioid adenocarcinoma (P<0.0001), early-stage disease (P=0.006), complete response to chemotherapy (P<0.05), and a low serum level of CA125 (P=0.02). High percentage of cells expressing ALDH1 was associated with a longer overall survival time (P=0.01) and disease-free survival time (P=0.006) by log-rank test. In contrast to its function in breast cancer, ALDH1 was a favorable prognostic factor in ovarian carcinoma. ALDH1 therefore may have a different function in ovarian cancer than it does in breast cancer.

Show MeSH

Related in: MedlinePlus

Immunoreactivity patterns of ALDH1 in ovarian serous adenocarcinomas (A-C) and endometrioid adenocarcinomas (D-F). A, ALDH1-negative staining in serous carcinoma. B, ≤ 20% serous carcinoma cells show cytoplasmic staining for ALDH1. C, Diffuse positive staining for ALDH1 in serous carcinoma. D, ALDH1-negative staining in endometrioid adenocarcinoma. E, ≤ 20% endometrioid carcinoma cells show cytoplasmic staining for ALDH1. F, Diffused positive staining for ALDH1 in endometrioid carcinoma. (Original magnification X200).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2692456&req=5

Figure 1: Immunoreactivity patterns of ALDH1 in ovarian serous adenocarcinomas (A-C) and endometrioid adenocarcinomas (D-F). A, ALDH1-negative staining in serous carcinoma. B, ≤ 20% serous carcinoma cells show cytoplasmic staining for ALDH1. C, Diffuse positive staining for ALDH1 in serous carcinoma. D, ALDH1-negative staining in endometrioid adenocarcinoma. E, ≤ 20% endometrioid carcinoma cells show cytoplasmic staining for ALDH1. F, Diffused positive staining for ALDH1 in endometrioid carcinoma. (Original magnification X200).

Mentions: Diffuse cytoplasmic staining with moderate intensity was observed in different proportion of the tumor cells. Very strong cytoplasmic and nuclear staining was observed in stromal cells. The expression in epithelial cancer cells was scored and subjected for statistical analysis. The percentage of positive cancer cells varied from <5 % to > 50% in our patient population (Fig. 1)


ALDH1 expression correlates with favorable prognosis in ovarian cancers.

Chang B, Liu G, Xue F, Rosen DG, Xiao L, Wang X, Liu J - Mod. Pathol. (2009)

Immunoreactivity patterns of ALDH1 in ovarian serous adenocarcinomas (A-C) and endometrioid adenocarcinomas (D-F). A, ALDH1-negative staining in serous carcinoma. B, ≤ 20% serous carcinoma cells show cytoplasmic staining for ALDH1. C, Diffuse positive staining for ALDH1 in serous carcinoma. D, ALDH1-negative staining in endometrioid adenocarcinoma. E, ≤ 20% endometrioid carcinoma cells show cytoplasmic staining for ALDH1. F, Diffused positive staining for ALDH1 in endometrioid carcinoma. (Original magnification X200).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2692456&req=5

Figure 1: Immunoreactivity patterns of ALDH1 in ovarian serous adenocarcinomas (A-C) and endometrioid adenocarcinomas (D-F). A, ALDH1-negative staining in serous carcinoma. B, ≤ 20% serous carcinoma cells show cytoplasmic staining for ALDH1. C, Diffuse positive staining for ALDH1 in serous carcinoma. D, ALDH1-negative staining in endometrioid adenocarcinoma. E, ≤ 20% endometrioid carcinoma cells show cytoplasmic staining for ALDH1. F, Diffused positive staining for ALDH1 in endometrioid carcinoma. (Original magnification X200).
Mentions: Diffuse cytoplasmic staining with moderate intensity was observed in different proportion of the tumor cells. Very strong cytoplasmic and nuclear staining was observed in stromal cells. The expression in epithelial cancer cells was scored and subjected for statistical analysis. The percentage of positive cancer cells varied from <5 % to > 50% in our patient population (Fig. 1)

Bottom Line: Expression of ALDH1 was found in 48.9% of the samples.Fisher's exact test suggested that high expression of ALDH1 was significantly associated with endometrioid adenocarcinoma (P<0.0001), early-stage disease (P=0.006), complete response to chemotherapy (P<0.05), and a low serum level of CA125 (P=0.02).High percentage of cells expressing ALDH1 was associated with a longer overall survival time (P=0.01) and disease-free survival time (P=0.006) by log-rank test.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

ABSTRACT
Aldehyde dehydrogenase 1 (ALDH1), a detoxifying enzyme responsible for the oxidation of intracellular aldehydes, was shown to have a function in the early differentiation of stem cells, through its function in oxidizing retinol to retinoic acid. It has been shown that ALDH1 is a predictor of poor clinical outcome in breast cancer. The authors hypothesized that the level of ALDH1 expression may be correlated with the clinical outcome of patients with ovarian cancer. Immunohistochemical staining of ALDH1 expression was analyzed in 442 primary ovarian carcinomas using tissue microarray. The associations between the expression of the ALDH1 and clinical factors (diagnosis, tumor grade, stage, and clinical response to chemotherapy), as well as overall and disease-free survival, were analyzed. Expression of ALDH1 was found in 48.9% of the samples. Fisher's exact test suggested that high expression of ALDH1 was significantly associated with endometrioid adenocarcinoma (P<0.0001), early-stage disease (P=0.006), complete response to chemotherapy (P<0.05), and a low serum level of CA125 (P=0.02). High percentage of cells expressing ALDH1 was associated with a longer overall survival time (P=0.01) and disease-free survival time (P=0.006) by log-rank test. In contrast to its function in breast cancer, ALDH1 was a favorable prognostic factor in ovarian carcinoma. ALDH1 therefore may have a different function in ovarian cancer than it does in breast cancer.

Show MeSH
Related in: MedlinePlus